• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and Enzalutamide.

作者信息

Taneja Samir S

出版信息

J Urol. 2018 Nov;200(5):945. doi: 10.1016/j.juro.2018.08.026. Epub 2018 Aug 16.

DOI:10.1016/j.juro.2018.08.026
PMID:30360342
Abstract
摘要

相似文献

1
Re: Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and Enzalutamide.
J Urol. 2018 Nov;200(5):945. doi: 10.1016/j.juro.2018.08.026. Epub 2018 Aug 16.
2
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.种系 DNA 修复基因突变与一线接受阿比特龙和恩杂鲁胺治疗的转移性去势抵抗性前列腺癌男性的结局
Eur Urol. 2018 Aug;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035. Epub 2018 Feb 10.
3
Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.胚系 DNA 修复基因突变与阿比特龙或恩杂鲁胺在转移性去势抵抗性前列腺癌患者中的疗效。
Eur Urol Focus. 2019 Sep;5(5):745-747. doi: 10.1016/j.euf.2019.02.011. Epub 2019 Feb 21.
4
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.Wnt信号通路激活突变与去势抵抗性前列腺癌对一线阿比特龙和恩杂鲁胺的耐药性相关。
Eur Urol. 2020 Jan;77(1):14-21. doi: 10.1016/j.eururo.2019.05.032. Epub 2019 Jun 5.
5
Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.比较阿比特龙和恩杂鲁胺在转移性去势抵抗性前列腺癌中的临床疗效和安全性：系统评价和荟萃分析。
J Oncol Pharm Pract. 2021 Apr;27(3):614-622. doi: 10.1177/1078155220929414. Epub 2020 Jun 12.
6
Re: Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.回复：Wnt信号通路激活突变与去势抵抗性前列腺癌对一线阿比特龙和恩杂鲁胺的耐药性相关。
Eur Urol. 2020 Mar;77(3):393. doi: 10.1016/j.eururo.2019.10.014. Epub 2019 Nov 12.
7
Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean?转移性去势抵抗性前列腺癌接受阿比特龙或恩杂鲁胺治疗时纯合子HSD3B1(1245C)遗传与不良预后：这意味着什么？
Ann Oncol. 2020 Sep;31(9):1103-1105. doi: 10.1016/j.annonc.2020.06.009. Epub 2020 Jun 24.
8
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.阿比特龙联合泼尼松与恩杂鲁胺治疗转移性去势抵抗性前列腺癌患者的健康相关生活质量：一项 II 期随机试验结果。
Eur Urol. 2019 Jun;75(6):940-947. doi: 10.1016/j.eururo.2018.12.015. Epub 2018 Dec 24.
9
Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.阿比特龙与恩杂鲁胺序贯治疗转移性去势抵抗性前列腺癌男性患者的回顾性研究
Prostate. 2017 Jan;77(1):33-40. doi: 10.1002/pros.23246. Epub 2016 Aug 16.
10
Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.阿比特龙和恩杂鲁胺治疗无法克服具有同源纯合 HSD3B1 c.1245C 基因型的转移性去势抵抗性前列腺癌男性的不良结局。
Ann Oncol. 2020 Sep;31(9):1178-1185. doi: 10.1016/j.annonc.2020.04.473. Epub 2020 May 5.